Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Depression, Cannabis Use Disorder, HIV
Phase NA
Enrollment 280
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

To elucidate mechanisms of substance use disorders (SUD) and comorbid mental illnesses in people living with HIV (PLWH), the study team seeks to investigate reward and pain circuitry in cannabis use and depression comorbidity, two highly prevalent conditions in PLWH. The study team proposes a tightly integrative study to test the overall hypothesis that cannabis use and depression in young PLWH have an additive effect, inducing both reward deficits and pain hypersensitivity, and that this pattern will predict worse outcomes at 1 year follow-up.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: MRI Study — fMRI Tasks

Primary Outcomes

  • Addiction Severity Index (ASI) (Up to 1 year)
  • Montgomery Asberg Depression Rating Scale (MADRS) Scale (Up to 12 months)
  • Temporal Experience of Pleasure Scale (TEPS) (Up to 12 months)
  • Neural Circuitry measured by MRI (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-01
Completion: 2027-07-30
Eligibility
Age: 18 Years – 59 Years
Sex: ALL
Volunteers: false
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Vilma Gabbay, MD (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Vilma Gabbay, MD
305-243-2382
vxg595@med.miami.edu
Jasmine Agreda, BS
305-243-5510
jja145@med.miami.edu
University of Miami
Joanna Starrels, MD
University of Miami
Interventions
  • Behavioral: MRI Study — fMRI Tasks
Study Locations (1 sites)
University of Miami, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: * HIV seropositivity confirmed with lab report, medical records, or HIV testing. * Between the ages of 18-39 years * Fluency in English or Spanish * Ability to provide informed consent and perform study procedures, including estimated full-scale intelligence quotient (IQ) \>75 to ensure that participants are able to understand the study. * Cannabis users: To capture a wide range of cannabis use frequency, meeting Diagnostic and Statistical Manual 5 (DSM-5) criteria for Cannabis use Disorder (CUD) will not be required. However, in order to ensure sufficient exposure, cannabis use will be significant (self-reported use on ≥20 of the prior 30 days and positive THC urine toxicology). * Depressed: In order to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of ≥12 on the Montgomery Asberg Depression Rating Scale (MADRS). Exclusion Criteria: * Perinatally acquired HIV infection, as early neurodevelopmental alterations and HIV legacy effects may exist in this group * Pregnancy or lactation * Current Substance Use Disorder other than cannabis or nicotine * Certified for or self-reported medical cannabis use, or intent to become certified * Current cocaine use by self-report or urine toxicology * central nervous system (CNS) disease or injury, or neuro-degenerative disease * Unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis); * Severe medical illness such as end-stage renal disease, heart failure, cirrhosis, or cancer * MRI contraindication such as claustrophobia, metallic ink tattoos, or pacemaker. Depressed cannabis non-users: * At baseline, all participants will be psychotropic-medication-free for ≥1 month prior to study enrollment (or ≥3 months for medications with longer half-lives). Benzodiazepines and sleeping aids taken on an as-needed basis will be allowed, however we will require a 4-day abstinence period before the scan. * Exclusionary are participants with a DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. disorder (PTSD) are not uncommon among depressed individuals and will be * Anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress are allowed as long as depressive symptoms are primary. atypical of depression. • Suicidal ideations (SI) without a specific plan (defined as passive SI) are common in depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the participant will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission. Depressed cannabis users: • Exclusion criteria will be the same as depressed cannabis non-users except for cannabis use. Non-depressed cannabis users: • Will have no major psychiatric conditions other than cannabis use/disorder. Non-depressed cannabis non-users: • Exclusion criteria will be the same as for non-depressed cannabis users; in addition participants will not report cannabis use in the prior 90 days and have a urine toxicology test negative for cannabis.
Conditions Cancer
Phase NA
Enrollment 248
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the effectiveness of Digital storytelling (DST) in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese survivors of childhood cancer. Participants in the experimental group will be divided into groups of 6 to 8 childhood cancer survivors to receive the intervention, which comprises four workshops. Each workshop will last 2.5 hours and will be conducted by a qualified interventionist. Parents are not required to attend the workshop. The investigators will provide a waiting room for them. Parents will also be provided with a leaflet developed by Hong Kong Department of Health which contains self-help material for depression. No intervention will be carried out among participants in the control group. However, customary care including medical follow-up, medication prescription, and nursing interventions will be provided, as usual. Parents will also be provided with a leaflet containing self-help materials for depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Digital storytelling — DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.

Primary Outcomes

  • Depressive symptoms: Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC) (The CES-DC will be conducted immediately after the completion of the intervention, and at 1-, 3- and 6-month follow-up via telephone interview.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-16
Completion: 2026-09-12
Eligibility
Age: 13 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 248 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Collaborators: Hong Kong Children's Hospital, Research Grants Council, Hong Kong
Principal Investigators:
  • Ka Yan Ho, phd (PRINCIPAL_INVESTIGATOR) - The Hong Kong Polytechnic University
Contact Information
Study Contact:
Ka Yan Ho, PhD
+8527666417
kyeva.ho@polyu.edu.hk
Ting MAO
66754757
23040516R@connect.polyu.hk
The Hong Kong Polytechnic University,
Interventions
  • Other: Digital storytelling — DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.
Study Locations (1 sites)
The Hong Kong Polytechnic University,, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * (1) age between 13 and 18 years; * (2) able to speak Cantonese and read Chinese; and * (3) completed the active treatment of cancer. Exclusion Criteria: * survivors with mental and behavioural problems documented in their medical records.
Conditions Perimenopause, PMDD
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: transcutaneous auricular neurostimulation (tAN) — Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)

Primary Outcomes

  • Daily Record of Severity of Problems (DRSP) (Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.)
  • Green Climacteric Scale (Participants will complete this measure monthly from study initiation until the end of the study, about three months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-10
Completion: 2027-03
Eligibility
Age: 18 Years – 55 Years
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Texas Christian University
Collaborators: Spark Biomedical, Inc.
Principal Investigators:
  • Sarah E Hill, PhD (PRINCIPAL_INVESTIGATOR) - Texas Christian University
Contact Information
Study Contact:
Sarah E Hill, PhD
817-257-6424
s.e.hill@tcu.edu
Savannah A Hastings, M.S.
817-257-4989
s.a.hastings@tcu.edu
Sarah E Hill, PhD
817-257-6424
s.e.hill@tcu.edu
Texas Christian University
Interventions
  • Device: transcutaneous auricular neurostimulation (tAN) — Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)
Study Locations (1 sites)
Texas Christian University, Fort Worth, Texas 76109 United States
Eligibility Criteria
PMS/PMDD Study: Inclusion Criteria: * Assigned female at birth * Age 18 to 45 * Naturally cycling * Regularly occurring menstrual cycle * Must identify as having PMS or PMDD * Reliable ability to complete online study surveys Exclusion Criteria: * Using hormonal birth control * Pregnant or lactating/breastfeeding * History of seizures * Implanted devices * Current or previous diagnosis of any heart conditions * Abnormal ear anatomy * Non-removable piercings on the ear * Recent ear infection * Taking SSRIs * Taking steroids * Taking hormone therapy * If the participant anticipates starting or stopping prescription medications during the study period * Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.) * Participant has a history traumatic brain injury within the past 12 months * Must not have any other mental illness or mood disorder Perimenopause Study: Inclusion Criteria: * Assigned female at birth. * Age 40 to 55 * Must have newly variable menstrual cycles or report identifying as perimenopausal * Reliable ability to complete online study surveys Exclusion Criteria: * Using hormonal birth control * Pregnant or lactating/breastfeeding * History of seizures * Implanted devices * Current or previous diagnosis of any heart conditions * Abnormal ear anatomy * Non-removable piercings on the ear * Recent ear infection * Taking SSRIs * Taking steroids * Taking hormone therapy * If the participant anticipates starting or stopping prescription medications during the study period. * Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.) * Participant has a history traumatic brain injury within the past 12 months * have a hysterectomy In both studies we will confirm that participants are symptomatic shortly following enrollment.
Conditions Hypertension
Phase NA
Enrollment 390
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Background: Isometric resistance exercises (IREs) have great potential to improve blood pressure (BP) control. However, the effectiveness of IREs in reducing HT is still unknown because their hypotensive effects have not been detected using ambulatory BP measurements (ABPM), which are the current standard for BP measurement. Methods: This first adequately-powered RCT will involve 390 patients with HT who do not meet the current physical activity guidelines defined by the World Health Organization. Participants will be randomly assigned in a 1:1 ratio using stratified and blocked randomization to either the IRE (wall squat) group or stretching exercise (active control) group. A well-structured, widely accepted, and validated 24-week wall squat program (2 minutes per exercise, 2 minutes of rest between sets, and 3 sessions per week) will be implemented, as it has been commonly used in previous research. Adherence to the program will be monitored using smartwatches, and regular contact with patients through social media will help ensure adherence. All patients will be followed up for 1 year to investigate the long-term effects of IREs on BP. Control group will receive exact same treatment except that IRE is replaced by frequency-matched and time-matched stretching exercise. The primary outcome measure will be systolic daytime ABPM BP at 24 weeks. Secondary outcome measures will include other BP and ABPM parameters at 12 weeks, 24weeks and 1year, cfPWV at baseline, 24 weeks and 1year, and FMD at baseline and 24weeks. Safety data will be collected and reported.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: isometric wall exercise — Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
  • Behavioral: passive stretching — A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used

Primary Outcomes

  • daytime systolic blood pressure (BP) assessed via ambulatory blood pressure monitoring (ABPM) (24-week after recruitment (immediate post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2027-09-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 390 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Eric Kam-Pui Lee, MSc, FRACGP
22528462
lkp032@cuhk.edu.hk
Eric Kam-Pui Prof Lee
22528462
lkp032@cuhk.edu.hk
Lek Yuen General Outpatient Clinic
kam pui Lee, Msc
85260996560
lkp032@cuhk.edu.hk
School of public health and primary care
Interventions
  • Behavioral: isometric wall exercise — Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
  • Behavioral: passive stretching — A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
Study Locations (2 sites)
Lek Yuen General Outpatient Clinic, Hong Kong, 00000 Hong Kong
School of public health and primary care, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * a suboptimal daytime SBP of \>135-160 mmHg on a 24-h ABPM * reported no regular physical activity or less than that recommended for adults by the World Health Organization (e.g. \<150 minutes of moderate-intensity aerobic exercise per week) * on stable doses of anti-HT medication(s) for ≥4 weeks if the patient is receiving drug treatments; * agree for no drug changes during the intervention period (24 weeks); Exclusion Criteria: * cannot provide informed consent * unwillingness to repeat ABPM * relative contraindications to ABPM (i.e. diagnosed atrial fibrillation, nighttime workers, occupational drivers, or patients with bleeding tendencies) * severe osteoarthritis pending knee replacement surgery * known secondary HT * use of ≥3 anti-HT medications at maximum doses or ≥4 anti-HT medications * SBP or DBP are \>160 mmHg or \>100 mmHg, respectively, on ABPM at baseline or at 12 weeks follow-up to ensure safety * pregnancy/breastfeeding * active malignancy
Conditions Advanced Chronic Liver Disease
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease. The main question it aims to answer are: \- what are the cut-off values for non-invasive tests (NITs) (including LSM, SSM) that predict the presence and occurrence of hepatic decompensation in individuals with advanced chronic liver disease? Participants will undergo regular study visits involving non-invasive tests (LSM, SSM) and assessments to monitor hepatic decompensation over the study period.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of patients diagnosed with portal hypertension using elastography techniques (At baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-10
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Information
Study Contact:
Amine Benmassaoud, MD
514-934-1934
amine.benmassaoud@mcgill.ca
Olivia Geraci, BSc
514-934-1934
olivia.geraci@muhc.mcgill.ca
Amine Benmassaoud, MD
5149341934
amine.benmassaoud@mcgill.ca
McGill University Health Centre
Interventions
N/A
Study Locations (1 sites)
McGill University Health Centre, Montreal, Quebec H3G1A4 Canada
Eligibility Criteria
Inclusion Criteria: * Age above 18years old * Advanced chronic liver disease (defined as LSM ≥ 10kPa) * Ability to provide informed consent Exclusion Criteria: * Transjugular intrahepatic portosystemic shunt * previous liver transplantation * Abnormality of the porto-mesenteric system (portal vein thrombosis, splenic vein thrombosis, splenectomy, portal cavernomatous transformation, porto-caval shunts) * Hematological malignancy
Conditions Insomnia (Self-reported, Non-diagnosed),...
Phase NA
Enrollment 94
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate the feasibility and the effect of self-acupressure on improving insomnia among the elderly with hypertension who reported insomnia (using the Insomnia Severity Index questionnaire) The main questions it aims to answer are: * Is the proposed intervention feasible to deliver to the target population in terms of recruitment, retention, adherence, and completion of outcome assessments? * Does self-acupressure improve insomnia among the elderly with hypertension? Researchers will compare participants in the self-acupressure group (practice acupressure at home for 28 days) and the enhanced standard care group to see the effectiveness of acupressure in improving insomnia for hypertensive elderly individuals. Participants in the self-acupressure group will be instructed how to locate and perform acupressure, then they will be asked to practice acupressure at home for 28 days (once a day). Participants in the enhanced standard care group will receive training on how to apply sleep hygiene rules and will be asked to follow sleep hygiene rules for 28 days.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Acupressure to improve insomnia — The acupressure protocol of the intervention was developed and validated by 6 traditional and hypertensive experts. Participants will be ask to perform acupressure with 6 acupoint including: Baihui (GV20), Yintang (GV29), Shenmen (HT\&0\< Sanyinjao (SP6), Zushalin (ST36) at nightime (30 mins before going to bed) in 28 days.Each acupoint must be stimulated in 2 mins.

Primary Outcomes

  • Insomnia severity (Insomnia severity will be measured at 3 time points: Baseline, Week 4, and Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-30
Completion: 2027-03-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Phenikaa University
Contact Information
Study Contact:
Huong Hoang, PhD
+84 0982501850
huong.hoangthixuan@phenikaa-uni.edu.vn
Huong Hoang
+84 0982501850
huong.hoangthixuan@phenikaa-uni.edu.vn
Son Tay general hospital
Interventions
  • Other: Acupressure to improve insomnia — The acupressure protocol of the intervention was developed and validated by 6 traditional and hypertensive experts. Participants will be ask to perform acupressure with 6 acupoint including: Baihui (GV20), Yintang (GV29), Shenmen (HT\&0\< Sanyinjao (SP6), Zushalin (ST36) at nightime (30 mins before going to bed) in 28 days.Each acupoint must be stimulated in 2 mins.
Study Locations (1 sites)
Son Tay general hospital, Hanoi, Son Tay 100000 Vietnam
Eligibility Criteria
Inclusion Criteria: * Hypertention patient who are ≥ 60 years old * Having Insomnia Severity Index score ≥ 11 * Having Karnofsky score ≥ 80. Exclusion Criteria: * Patients who are currently participating in clinical trials for the treatment of insomnia. * Patients who are currently receiving pharmacological treatment for insomnia. * Patients with concomitant cardiovascular conditions, such as heart failure; patients with an implanted pacemaker; patients who have an indication for catheter-based cardiovascular intervention; or patients who have an indication for cardiovascular surgery. * Patients with psychiatric disorders, such as depression, generalized anxiety disorder, or bipolar disorder.
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) is a rare but severe complication of pulmonary embolism (PE). CTEPH is evoked in patients with persistent dyspnea. According to international guidelines, symptomatic patients with perfusion defects on lung scan and Pulmonary Hypertension (PH)-likely transthoracic echo (TTE) must be evaluated in Pulmonary Hypertension (PH)-centers with right heart catheterism, to confirm or rule out the presence of precapillary Pulmonary Hypertension (PH), and precise the group of Pulmonary Hypertension (PH).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Biological: blood sample — to realize proteomic analysis.

Primary Outcomes

  • Proteomic pattern associated with the diagnosis of Chronic thromboembolic pulmonary hypertension (CTEPH) (Day: 0)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-09
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Principal Investigators:
  • Laurent BERTOLETTI, PhD (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Universitaire de Saint Etienne
Contact Information
Study Contact:
Laurent BERTOLETTI, MD PhD
(0)477127770
laurent.bertoletti@chu-st-etienne.fr
Carine LABRUYERE
(0)477120826
carine.labruyere@chu-st-etienne.fr
Laurent BERTOLETTI, MD PhD
CHU de SAINT-ETIENNE
Interventions
  • Biological: blood sample — to realize proteomic analysis.
Study Locations (1 sites)
CHU de SAINT-ETIENNE, Saint-Etienne, 42055 France
Eligibility Criteria
Inclusion Criteria: * Patient with a suspicion of Chronic thromboembolic pulmonary hypertension (CTEPH) with a combination of a perfusion lung scan and transthoracic perfusion scan and transthoracic echocardiography compatible with the diagnosis (according to French recommendations) * Patients who require a right heart catheterization. * Patient affiliated or entitled to a social security plan * Patient having received informed information about the study informed about the study Exclusion Criteria: * Patient with a normal perfusion lung scan * Person under legal guardianship
Conditions Cardiovascular Disease Prevention, Cardi...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are: * Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke? * Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes? * Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare? Researchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors. Participants will: * Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6. * Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare * Keep a log of their blood pressure

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Longitudinal, Individualized Health Coaching — During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.

Primary Outcomes

  • 10 - Year Atherosclerotic Cardiovascular Disease Risk Score (From enrollment to the end of study participation at 6 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2027-07-01
Eligibility
Age: 40 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rush University Medical Center
Collaborators: The Physicians Foundation
Principal Investigators:
  • Daniel Luger, MD (PRINCIPAL_INVESTIGATOR) - Rush University Medical Center
Contact Information
Study Contact:
Daniel Luger, MD
\(708) 660-2328
daniel_luger@rush.edu
Daniel Luger, MD
(312) 942-5020
daniel_luger@rush.edu
Rush University Medical Center
Interventions
  • Behavioral: Longitudinal, Individualized Health Coaching — During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.
Study Locations (1 sites)
Rush University Medical Center, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion: * Patient is a participant at a CHI sponsored, community screening event * Patient provides informed consent and willingness to participate for the duration of the study * English or Spanish speaking * Age 40-75 years old * At least 1 cardiometabolic risk factor at suboptimal level, defined as one or more of the following at initial screening: * Systolic BP greater than 130mmHg and/or diastolic BP greater than 80mmHg. * Body mass index (BMI) greater than 30 〖kg/m〗\^2 * Total cholesterol greater than 200 mg/dL * Triglycerides greater than 150 mg/dL * Low density lipoprotein (LDL) greater than 130 mg/dL * High density lipoprotein (HDL) less than 40 mg/dL in men or less than 50 mg/dL in women * Hemoglobin A1c greater than or equal to 5.7% * 10-year ASCVD score greater than 5% * Access to a telehealth compatible device Exclusion: * Adults unable to provide informed consent or unwilling to participate for study duration * Speaks language other than English or Spanish * Younger than 40 years old or older than 75 years old * All cardiometabolic risk factors at optimal levels * No telehealth compatible device * Pregnant patients
Conditions Portal Hypertension, Chronic Liver Disea...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative to the traditional hepatic venous pressure gradient (HVPG) method in patients with portal hypertension due to chronic liver disease. The main questions it aims to answer are: * What is the correlation between EUS-PPG and HVPG measurements in patients with portal hypertension due to cirrhosis? * Can EUS-PPG serve as a reliable and less invasive alternative to HVPG for assessing portal pressure? * What are the safety outcomes associated with EUS-PPG compared to HVPG? Researchers will compare EUS-PPG measurements with HVPG measurements within the same patients to assess whether EUS-PPG provides accurate and clinically comparable portal pressure readings while reducing procedural risks. Participants will: * Be adults aged 18 to 85 with a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement. * Undergo both EUS-PPG and HVPG measurements within a seven-day window to allow for direct comparison of results. * Receive standard clinical care for their condition, including routine diagnostic evaluations and portal hypertension management as needed. * Be monitored for safety outcomes, including adverse events such as bleeding, infection, perforation, and any other complications related to the procedure. * Provide relevant demographic and clinical data, including liver disease history, Child-Pugh and MELD scores, and portal hypertension-related complications such as varices or ascites.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement — Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
  • Diagnostic Test: Hepatic Venous Pressure Gradient (HVPG) Measurement — Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.

Primary Outcomes

  • Correlation between the portosystemic pressure gradient (PPG) measured directly via endoscopic ultrasonography (EUS-PPG) and measured via the hepatic venous pressure gradient (HVPG). (7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-16
Completion: 2026-12
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundacio Privada Mon Clinic Barcelona
Contact Information
Study Contact:
Principal Investigator
+34932275400
contacta@clinic.cat
Hospital Clinic de Barcelona
Juan Carlos García-Pagan
Hospital Clinic de Barcelona
Interventions
  • Diagnostic Test: Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement — Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
  • Diagnostic Test: Hepatic Venous Pressure Gradient (HVPG) Measurement — Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.
Study Locations (1 sites)
Hospital Clinic de Barcelona, Barcelona, 08036 Spain
Eligibility Criteria
Inclusion Criteria: * Subjects must be 18 to 85 years of age inclusive, at the time of signing the informed consent form. * Subjects who have a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement. * Subjects capable of giving signed informed consent. Exclusion Criteria: * Pregnancy. * Significant bleeding risk (International Normalized Ratio (INR) \> 1.5 OR platelet count \< 50000). * Presence of active gastrointestinal bleeding at the time of screening * History of any blood thinner consumption (e.g. warfarin, heparin, novel roal anticoagulants) within the last 5 days. * Presence of massive ascites causing abdominal distension or requiring frequent therapeutic paracentesis. * Subjects having received previous Transjugular Intrahepatic Portosystemic Shunt (TIPS) or Surgical Portosystemic Shunt. * Hepatocellular carcinoma not meeting Milan Criteria. * Presence of portal vein thrombosis or another suspected component of presinusoidal portal hypertension. * Presence of extra-hepatic cancer, terminal disease, or severe comorbidities significantly limiting life expectancy or affecting study participation. * Stenosis or surgical anatomical alterations of the gastrointestinal tract that could preclude endoscopic access with the echoendoscope.
Conditions Chronic Lung Disease, Pulmonary Hyperten...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Prospective observational study to determine if the PVD-B65 risk score for one-year mortality in patients with chronic lung disease and pulmonary hypertension (CLD-PH) can accurately risk stratify these patients and successfully predict one-year mortality from time of pulmonary hypertension diagnosis. PVD-B65 risk score was developed in a retrospective cohort of patients with CLD-PH, utilizing the presence of pulmonary fibrosis without emphysema, pulmonary vascular resistance (PVR) \> 5 woods units (WU), 6-minute walk distance (6MWD) \< 150 meters, B-natriuretic type peptide (BNP) \> 200 pg/mL or N-terminal pro-natriuretic type peptide (NT-proBNP) \> 300 pg/dL, and age \> 65 years as the score components.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Observational Study — * assignment of PVD-B65 score derived from standard of care testing * no therapeutic intervention or other treatment

Primary Outcomes

  • Prediction of one year mortality (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-01
Completion: 2028-09-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Temple University
Contact Information
Study Contact:
Shameek Gayen, MD
267-990-3630
shameek.gayen@tuhs.temple.edu
Shameek Gayen, MD
267-990-3630
shameek.gayen@tuhs.temple.edu
Temple University Hospital
Interventions
  • Diagnostic Test: Observational Study — * assignment of PVD-B65 score derived from standard of care testing * no therapeutic intervention or other treatment
Study Locations (1 sites)
Temple University Hospital, Philadelphia, Pennsylvania 19140 United States
Eligibility Criteria
Inclusion Criteria: * Eligibility criteria 1. Adult patients ≥ 18 years of age with chronic lung disease diagnosed via CT chest and/or PFT data and pre-capillary pulmonary hypertension diagnosed via right-heart catheterization (RHC, mPAP \> 20 mmHg, PVR \> 2 WU, and PCWP ≤ 15 mmHg) 1. Chronic lung disease diagnoses will include: COPD, IPF, other pulmonary fibrosis, non-fibrotic ILD, combined pulmonary fibrosis and emphysema, and advanced pulmonary sarcoidosis with parenchymal involvement 2. PFT criteria will include an FEV1/FVC \< 0.70 for the diagnosis of COPD 2. Willingness to make return visits and be available by telephone for the duration of the study. 3. Ability to participate in necessary testing, including ambulatory testing Exclusion Criteria: * Exclusion criteria 1. Patients with pulmonary hypertension but without associated chronic lung disease (i.e. idiopathic or group 1 PAH, PH with post-capillary component defined as PCWP \> 15 mmHg or group 2 PAH, CTEPH or group 4 PH, group 5 PH aside from sarcoidosis with parenchymal involvement) 2. Patients with uncontrolled severe systemic disease that could influence life expectancy (i.e. uncontrolled cardiovascular disease, active malignancy, etc.) 3. Prior lung and/or heart transplantation
Conditions Cardiovascular Diseases, Hypertension, D...
Phase NA
Enrollment 45000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Home-based multimodal cardiovascular screening — Self-administered home-based screening program: 7-day home BP, DBS biomarker self-sampling, digital questionnaire; structured digital return of results; threshold-based initiation of guideline-recommended pharmacotherapy and referral to clinical care.

Primary Outcomes

  • Rate of total major adverse cardiovascular events over 10 years (Within 10 years after randomization)
  • Number of initiated guideline-recommended pharmacotherapies for cardiovascular risk factors within 12 months (Within 12 months after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2037-12
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 45000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johan Sundström
Collaborators: Region Uppsala Public Health and Care
Principal Investigators:
  • Johan Sundström, MD, PhD (PRINCIPAL_INVESTIGATOR) - Uppsala University
  • Anders Wanhainen, MD, PhD (PRINCIPAL_INVESTIGATOR) - Uppsala University
Contact Information
Study Contact:
Johan Sundström, MD, PhD
+46 70 422 52 20
johan.sundstrom@uu.se
Sundström
+46 70 422 52 20
johan.sundstrom@uu.se
Uppsala University Hospital
Sundström
Uppsala University Hospital
Interventions
  • Behavioral: Home-based multimodal cardiovascular screening — Self-administered home-based screening program: 7-day home BP, DBS biomarker self-sampling, digital questionnaire; structured digital return of results; threshold-based initiation of guideline-recommended pharmacotherapy and referral to clinical care.
Study Locations (1 sites)
Uppsala University Hospital, Uppsala, 751 85 Sweden
Eligibility Criteria
Inclusion Criteria: * Resident in Region Uppsala, Sweden * Turning 50, 55, 60, 65, 70 or 75 years during recruitment period * Able to provide informed consent Exclusion Criteria: * Inability to provide informed consent * Protected identity
Conditions Preeclampsia (PE), Pregnancy
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia (PE) is a serious pregnancy complication characterized by new-onset hypertension and signs of maternal organ dysfunction, often accompanied by placental abnormalities and systemic endothelial dysfunction. PE is associated with adverse maternal and perinatal outcomes and confers an increased long-term risk of cardiovascular and metabolic disease for both mother and offspring. This prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with preeclampsia. Pregnant women with a clinical diagnosis of PE according to current obstetric guidelines will be recruited at their initial presentation either in the in- or outpatient clinic or in the delivery ward, respectively and followed through late pregnancy, delivery, and early postpartum. Participants will undergo study visits during pregnancy, sample collection at delivery, and a postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of pregnancies complicated by preeclampsia. Data and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of preeclampsia-associated biological and clinical changes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 1 (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Adiposity (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 2 (from study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Cytokine Profile (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Lipid profile (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 3 (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Echocardiography (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Infant outcomes: hemodynamic assessment (At birth and at 8-12 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-01
Completion: 2036-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Graz
Contact Information
Study Contact:
Christina Stern, Dr.med
+43 316 385 86306
christina.stern@medunigraz.at
Ursula Hiden, PhD
+43 316 385 17837
ursula.hiden@medunigraz.at
Ursula Hiden, PhD
Department of Obstetrics and Gynecology, Medical University of Graz
Interventions
N/A
Study Locations (1 sites)
Department of Obstetrics and Gynecology, Medical University of Graz, Graz, 8036 Austria
Eligibility Criteria
Inclusion Criteria: * Ongoing pregnancy with preeclampsia regardless the gestational age diagnosed for PE Exclusion Criteria: * Maternal or fetal genetic abnormalities